Cited 2 times since 2011 (0.1 per year) source: EuropePMC Expert opinion on investigational drugs, Volume 20, Issue 11, 7 1 2011, Pages 1517-1522 Low molecular weight heparins in the treatment of lung cancer. Mellema WW, Smit EF, Dingemans AM
Introduction
Lung cancer is the major cause of cancer-related death. Venous thromboembolic events (VTEs) occur frequently in lung cancer and are a poor prognostic marker. For prevention and treatment of VTE, low molecular weight heparins (LMWH) are superior to vitamin K antagonists. There is some evidence that LMWH may improve survival in cancer patients.
Areas covered
The areas covered in this review are: lung cancer and VTEs; role of LMWH in treatment of VTEs; anticancer mechanism of heparins and clinical trials with LMWH in lung cancer.
Expert opinion
LMWH plays an important role in prevention and treatment of VTEs in lung cancer. Although there is evidence from both preclinical data and retrospective analysis of clinical trials that LMWH may prolong survival this is not confirmed by prospective randomized clinical trials. Several clinical trials on this subject in lung cancer are ongoing and have to be awaited.
